Checkmate Pharmaceuticals, a clinical stage immuno-oncology biotech developing therapies for solid tumors, raised $75 million by offering 5 million shares at $15, within the range of $14 to $16. Checkmate Pharmaceuticals plans to list on the Nasdaq under the symbol CMPI. BofA Securities, Jefferies and BMO Capital Markets acted as lead managers on the deal.
